Cilofexor (GS-9674) is a potent FXR agonist (EC50 = 43 nM) (Figure 4) with a potential for the treatment of NASH due to its anti-inflammatory and anti-fibrotic effects. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.